This development is a strategic part of the company's commitment to bolstering its position in the advanced pharmaceutical intermediates segment
The initiation of the second clinical trial in the INTerpath program represents rapid expansion in research for additional tumor types for individualized neoantigen therapy, V940 (mRNA-4157)
The CVMP recommends the product for approval for the treatment and persistent killing of fleas
Sarclisa added to bortezomib, lenalidomide and dexamethasone (VRd) significantly reduced the risk of disease progression or death compared with VRd alone
his marks the 12th formulation facility under Akums, and the second in Baddi, a strategic move with an aim to enhance Akums’ manufacturing capabilities.
Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya
The acquisition will enable Cupid Limited to amplify its production capacity by 1.5 times the existing output
Multi-ethnic innovation helps all complexions appear clearer and more uniform
Global Ayurveda Festival organising in Thiruvananthapuram from 1st to 5th December
The full transition of Viatris' biosimilars operations to Biocon Biologics in Europe represents another significant milestone
Subscribe To Our Newsletter & Stay Updated
